| 赵晓伟,田坚,沈静雪,等.维格列汀对经二甲双胍治疗的肥胖2型糖尿病患者肺功能的影响[J].安徽医药,2016,20(2):369-373. |
| 维格列汀对经二甲双胍治疗的肥胖2型糖尿病患者肺功能的影响 |
| The effect of vildagliptin on pulmonary function in obese patients with type 2 diabetes treated with metformin |
| 投稿时间：2015-09-22 |
| DOI： |
| 中文关键词: 2型糖尿病 肥胖 维格列汀 氧化相关物质 二甲双胍 肺功能 |
| 英文关键词: type 2 diabetes obesity vildagliptin oxidative related substances metformin pulmonary function |
| 基金项目:沈阳市科技计划项目基金(No F13-220-9-10) |
|
| 摘要点击次数: 2949 |
| 全文下载次数: 93 |
| 中文摘要: |
| 目的 观察维格列汀对经二甲双胍治疗的肥胖2型糖尿病患者肺功能的影响,并评估该方案的有效性与安全性。 方法 选取肥胖的2 型糖尿病患者100例(均为二甲双胍单药控制不佳者),随机分为观察组(50例)和对照组(50例)。对照组给予二甲双胍(1 000 mg bid,po),观察组为二甲双胍(1000 mg bid,po)联合维格列汀(50 mg bid,po),两组患者规范治疗24周,比较两组患者治疗前后肺活量(VC)、用力肺活量(FVC)、一秒用力呼气流量(FEV1)、最大呼气峰流速(PEF)、最大自主通气量(MVV)、肺总量(TCL)、一秒率(FEV1/FVC)、肺一氧化碳弥散量(DLCO)、肺单位体积一氧化碳弥散量(DLCO/VA)、外周血清超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、活性氧类物质(ROS)活性及其丙二醛(MDA)浓度、体质量指数、腰围、糖化血红蛋白(HbA1C)、空腹血糖(FBG),餐后 2 h血糖(2hPBG)的变化情况,并记录治疗过程中的不良反应。结果 治疗后两组患者的VC、FVC、FEV1、PEF、MVV、TLC、FEV1/FVC、DLCO、DLCO/VA均高于治疗前(P＜0.05),治疗后对照组患者上述指标均低于观察组(P＜0.05)。治疗后,两组ROS、MDA、FBG、2hPBG、HbA1C、体质量指数、腰围均较治疗前降低,差异有统计学意义(P＜0.05),治疗后观察组上述指标明显低于对照组,差异有统计学意义(P＜0.05)；治疗后,SOD、GSH-Px活性较治疗前升高,差异有统计学意义(P＜0.05),治疗后观察组上述指标明显高于对照组,差异有统计学意义(P＜0.05),且治疗过程中两组的不良反应无统计学差异(P＞0.05),观察组头痛的发生率高于对照组(P＜0.05)。结论 维格列汀联合二甲双胍可有效纠正外周血清氧化与抗氧化物质的失衡来改善肥胖的2型糖尿病患者的肺功能,同时能降低患者的体质量指数、腰围等指标,且不增加低血糖风险,值得临床广泛推广。 |
| 英文摘要: |
| Objective To observe the effect of vildagliptin on pulmonary function in obese patients with type 2 diabetes treated with metformin,thereby evaluating its efficacy and safety.Methods Obese patients (100 cases) with type 2 diabetes were randomly divided equally into observation and control groups (n=50).The patients in the control group were given metformin (1000 mg bid,po),while the observation group given metformin (1000 mg bid,po) along with vildagliptin (50 mg bid,po).The treatment in both groups continued for 24 weeks.We also recorded in both groups the changes of pulmonary function index,oxydic and antioxidative index,body mass index (BMI),waist circumference (WC),glycosylated hemoglobinA1c (HbA1C),fasting plasma glucose (FBG),and 2-hour postprandial blood glucose(2hPBG).Results VC,FVC,FEV1,PEF,MVV,TLC,FEV1/FVC,DLCO and DLCO/VA in both groups after treatment were significantly increased (P<0.05),with the observation group significantly lower than the control group (P<0.05).ROS,MDA,FBG,2hPBG,HbA1C,BMI,and waist circumference were lower after treatment,all of which having statistical difference in the two groups (P<0.05).The corresponding data were also significantly lower in the observation group than the control group(P<0.05).The activity of SOD and GSH-PX were escalated after treatment in the two groups (P<0.05),and the observation group showed higher avtivity of SOD and GSH-PX (P<0.05). Conclusions Vildagliptin combined with metformin can effectively relieve the imbalance of the oxidative and related substances in the serum in the treatment of type 2 diabetes with obesity,thereby improving pulmonary function and reducing the BMI,and waist circumference,while also not increasing the risk of hypoglycemia.All these findings showed that this treatment regimen was worthy of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
